UroGen Pharma CFO resigns; reports FY2021 Jelmyto revenue $48M, net loss $110.8M

UroGen Pharma Ltd.

CFO Molly Henderson resigns effective March 25, 2022; replaced by Dong Kim (VP Finance).
FY2021 Jelmyto net product revenue $48.0M, up 307% YoY; Q4 revenue $16.2M, up 42% QoQ.
FY2021 net loss $110.8M ($4.96/share) vs $128.5M loss in prior year.
2022 revenue guidance $70-80M; operating expenses guided $140-160M; RTW financing expense $22-26M.
Closed $75M tranche of up to $100M senior secured term loan facility with Pharmakon Advisors.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dong (Don) Kim

Chief Financial Officer

URGN · UroGen Pharma Ltd.

Effective: 2022-03-25
Filed: March 21, 2022, 7:59 PM ET

Effective as of March 25, 2022 (the “Effective Date”), the Company appointed Dong (Don) Kim as Chief Financial Officer of the Company, as well as the Company’s principal financial officer and principal accounting officer, replacing Ms. Henderson in such capacities.

Departed

Molly Henderson

Chief Financial Officer

URGN · UroGen Pharma Ltd.

Effective: 2022-03-25
Successor: Dong (Don) Kim
Filed: March 21, 2022, 7:59 PM ET

On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dong (Don) Kim was appointed as Chief Financial Officer at UroGen Pharma Ltd..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective as of March 25, 2022 (the “Effective Date”), the Company appointed Dong (Don) Kim as Chief Financial Officer of the Company, as well as the Company’s principal financial officer and principal accounting officer, replacing Ms. Henderson in such capacities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Molly Henderson resigned as Chief Financial Officer at UroGen Pharma Ltd..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.

View on SEC.gov

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-22-080081

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.